ITGAV and gastric cancer: Notably, inhibition of the STAT3/NAT10/KLF5/ITGαV axis effectively suppressed liver metastasis in GC, suggesting that this axis could serve as a promising predictive biomarker and therapeutic target for GC with liver metastasis (Figure 7F).